← All trials
NCT05139225
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2021
- Primary completion
- Oct 31, 2023
- Completion date
- Oct 31, 2023
- First posted
- Dec 1, 2021
- Last posted
- Dec 1, 2021
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Memorial Sloan-Kettering Cancer CenterLead sponsor
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
- Trillium Therapeutics Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.